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Clinical Question 
What are the relative risks and benefits of combination contraceptives? 
Evidence-Based Answer 
The risks of using oral combination contraceptives include: a three- to sixfold increase in the 
incidence of venous thromboembolism (VTE) apparent by the fourth month of use and highest 
between six and 12 months of use; a two- to sixfold increase in the risk of ischemic stroke among 
women with a history of migraine; and an increase in cervical cancer risk after five or more years 
of use. (Strength of Recommendation [SOR]: B) 
For the use of oral combination contraceptives there is no associated increase in risk of weight 
gain (SOR: A) or breast cancer (SOR: B), and no consistent change in breast milk production 
(SOR: A), infant growth or weight (SOR: A), or bone mineral density (SOR: B). 
The benefits of oral combination contraceptive use include a lower incidence of colorectal cancer 
without regard to duration of use (SOR: B), a reduction in primary dysmenorrheal pain after one 
to three months of use (SOR: B), and improvement in acne in trials of six months of use. (SOR: 
A) 
There is little rigorous evidence that combination contraceptive use improves dysfunctional 
uterine bleeding (SOR: B) or that combination contraceptive use improves heavy menstrual 
bleeding more than other proposed treatments of low-dose danazol (Danocrine), mefenamic acid 
(Ponstel), or naproxen (Naprosyn). (SOR: B) 
Evidence Summary 
The risks and benefits of combination contraceptives have not been consistently studied in all 
routes of administration. Combination contraceptive use increases a woman's risk for VTE and 
ischemic stroke.1,2 Observational studies found one to three additional cases of VTE among 
10,000 women taking combination contraceptives for one year.1 The risk of ischemic stroke is 
also higher among combination contraceptive users with a history of migraines with aura.2,3 In 
absolute terms, measured as ischemic strokes per 10,000 women over 10 years, a woman 25 to 
29 years of age has a baseline ischemic stroke risk of 2.7; this risk increases to 4.0 if she uses 
oral contraceptives, 11.0 if she has migraines with aura, and 23.0 if she both uses oral 
contraceptives and has migraines with aura.2 
Cervical cancer risk increases with duration of combination contraceptive use longer than five 
years, even after adjusting for infection with human papillomavirus (relative risk [RR], 1.3 to 
2.5).4 
Regarding the quality or quantity of breast milk, a well-done systematic review found only low-
quality trials with conflicting evidence.5 Some found that combination contraceptive use 
decreases breast milk quality or quantity in women lactating postpartum, whereas other studies 
did not show a change.5 The yearly risk of pregnancy while using combination contraceptives 
ranges from 0 to 2.5 percent based on the method selected, for an effectiveness rate of 97.5 to 
100 percent with typical use.6 
Along with excellent effectiveness rates, combination contraceptives are beneficial in decreasing 
pain associated with primary dysmenorrhea and the number of acne lesions.7,8 Case-control and 
cohort studies have found an association between combination contraceptive use and a modest 
decrease in the risk of colorectal cancer (RR, 0.82 [95% confidence interval, 0.74 to 0.92]). 
However, these studies were generally of poor quality and did not control for other important 
factors (e.g., diet) for the development of colorectal cancer.9 
The side effects of headache and weight gain are not statistically significantly different between 
users and nonusers of combination contraceptives.2,10 Insufficient data exist to determine a 
relationship between combination contraceptive use and heavy menstrual bleeding, dysfunctional 
uterine bleeding, and bone mineral density.11-13 Data are lacking to prove that combination 
contraceptive use increases a woman's risk of developing breast cancer, cardiovascular disease, 
or endometriosis.1,14-16 
Recommendations from Others 
The World Health Organization (WHO) recommends that women with cardiovascular disease, 
uncontrolled hypertension, ischemic heart disease, a history of stroke, venous thromboembolic 
disease, migraine with aura, or a history of breast cancer, or who are smokers older than 35 years 
who smoke more than 15 cigarettes per day, should avoid combination contraceptive use.17 The 
WHO discourages combination contraceptives during the six weeks immediately postpartum for 
women desiring to breastfeed.17 
The American College of Obstetricians and Gynecologists recommends using alternate forms of 
contraception in women with the following conditions: migraine headaches, age older than 35 
years who smoke cigarettes, history of thromboembolic disease, coronary artery disease, 
congestive heart failure, cerebrovascular disease, those who are less than two weeks postpartum, 
hypertension or diabetes with vascular disease or age older than 35, hypertriglyceridemia, a 
history of breast cancer, systemic lupus erythematosus with vascular disease, nephritis, or 
antiphospholipid antibodies.18 
Clinical Commentary 
This review offers helpful risk values to provide to patients and would help facilitate a patient-
specific, targeted discussion of the relative risks and benefits of combination contraceptives. 
What is particularly helpful in this review is the breakdown of information on combination 
contraceptives into the categories of risks, nonrisks, and benefits. Fortunately, with the newer 
combination contraceptives, more options exist to select for the particular combination of 
hormones that best maximizes benefits and minimizes risks for any given patient. In addition, 
there is more information about the benefits of combination contraceptives with respect to 
ovarian cancer rates and treatment of endometriosis and ovarian cysts that may be relevant to 
select groups of patients. 
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